The study further investigated the origin and functional mechanisms of CD38hi macrophages in the context of AKI-CKD progression, and validated the therapeutic potential of targeting CD38 as a strategy to mitigate renal fibrosis.[52] Macrophages play dual roles as both “good guys” and “bad guys” in AKI. Here, CD38 is linked to chronic kidney disease.